AM-1488
Modify Date: 2024-04-05 17:45:09
AM-1488 structure
|
Common Name | AM-1488 | ||
|---|---|---|---|---|
| CAS Number | 2079895-60-4 | Molecular Weight | 383.42 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H17N3O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AM-1488AM-1488 is a potent, orally active glycine receptor (GlyR) potentiator (hGlyRα3 EC50=0.45 μM)[1][2]. |
| Name | AM-1488 |
|---|
| Description | AM-1488 is a potent, orally active glycine receptor (GlyR) potentiator (hGlyRα3 EC50=0.45 μM)[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | AM-1488 also potentiates native GlyRs in mouse spinal-cord neurons, which express mostly GlyRα1(β) and GlyRα3(β)[1]. Cell Viability Assay[1] Cell Line: Mouse spinal-cord neuron Concentration: 0.5 μM Incubation Time: 10 min Result: Increased the peak current evoked by a puff of 20 µM glycine in five out of five cells, from an average of 50.8 pA to an average of 222.2 pA. |
| In Vivo | AM-1488 (oral gavage; 20 mg/kg; once) treatment significantly reverse mechanical allodynia induced by nerve injury in a mouse model of neuropathic pain, without being confounded by sedation or motor side effects[1]. Animal Model: Mouse model of spared nerve injury (SNI)[1] Dosage: 20 mg/kg Administration: Oral gavage; 20 mg/kg; once Result: Produced a significant 94% reversal of tactile allodynia, and the unbound brain concentration was 2.8- and 1.6-fold higher than the mouse GlyRα1 and GlyRα3 EC50 values, respectively. Animal Model: Naive mice[1] Dosage: 20 mg/kg Administration: Oral gavage; 20 mg/kg; once Result: Showed not significantly different from mice treated with vehicle. |
| References |
| Molecular Formula | C19H17N3O4S |
|---|---|
| Molecular Weight | 383.42 |